Intest Res 2018; 16(3): 499-501  https://doi.org/10.5217/ir.2018.16.3.499
Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
Satoshi Motoya1, Mamoru Watanabe2, Hyo Jong Kim3, Young Ho Kim4, Dong Soo Han5, Hirotoshi Yuasa6, Junichi Tabira6, Naoki Isogawa6, Shoko Arai6, Isao Kawaguchi6, Toshifumi Hibi7
1IBD Center, Sapporo Kosei General Hospital, Sapporo, 2Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan, 3Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, 4Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 5Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea, 6Inflammation & Immunology, Pfizer Japan Inc, Tokyo, 7Center for Advanced IBD Research and Treatment, Kitasato University, Tokyo, Japan
Published online: July 30, 2018.
© Korean Association for the Study of Intestinal Diseases. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


This Article

e-submission

Archives

Official Journal of

Indexed/Covered by